Ovarian Cancer
Open Access
- 1 August 2001
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 6 (4) , 327-332
- https://doi.org/10.1634/theoncologist.6-4-327
Abstract
Ovarian cancer remains the most lethal gynecologic malignancy in women in the United States. Studies from this year's American Society of Clinical Oncology more clearly defined the role of chemotherapy in women with early stage disease and now suggest that essentially all women with invasive disease should receive chemotherapy that contains carboplatin. Studies in women with advanced disease continue to support the use of carboplatin and paclitaxel in the treatment of women with newly diagnosed disease although early data suggest that carboplatin and docetaxel might be an acceptable alternative. Platinum-resistant disease remains a therapeutic challenge. Small molecules that inhibit the function of the epidermal growth factor receptor, such as OSI-774, and novel classes of chemotherapeutic agents, including the acylfulvene MGI-114 and epothilone B and its analogue, BMS247550, all warrant further study in this disease.Keywords
This publication has 10 references indexed in Scilit:
- Combination Chemotherapy With Carboplatin and Docetaxel in the Treatment of Cancers of the Ovary and Fallopian Tube and Primary Carcinoma of the PeritoneumJournal of Clinical Oncology, 2001
- Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancerBritish Journal of Cancer, 2001
- Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid MalignanciesJournal of Clinical Oncology, 2000
- Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cellsInternational Journal of Cancer, 2000
- Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in Stage III and IV ovarian carcinomaCancer, 2000
- Epothilones and related structures – a new class of microtubule inhibitors with potent in vivo antitumor activityBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2000
- First-Line Chemotherapy With Epirubicin, Paclitaxel, and Carboplatin for Advanced Ovarian Cancer: A Phase I/II Study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study GroupJournal of Clinical Oncology, 1999
- Expression of Epidermal Growth Factor and Androgen Receptors in Ovarian CancerGynecologic Oncology, 1997
- Natural history and prognosis of untreated stage I epithelial ovarian carcinoma.Journal of Clinical Oncology, 1996
- Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapyBritish Journal of Cancer, 1995